Healthcare / Medical DevicesTel Aviv
$5185.00
-78.00 (-1.50%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 23% · confianza 25%
FCF escenarios
weak_data · normalized FCF $42.8M · quality 78.7/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
46/100
C
Piotroski
7/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$580M
P/E
11.3x
↓EV/EBITDA
460.0x
↑ROE
8.1%
↑Gross Margin
22.8%
↓Debt/Equity
0.07
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
+2.5%
FCF CAGR
+1.1%
FCF margin
4.6%
FCF / Net income
0.77x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $930.8M · net income $55.6M · FCF $42.8M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $930.8M | $930.8M | $920.4M | $916.2M | $863.3M |
| Net Income | $55.6M | $55.6M | $39.0M | $50.9M | $102.1M |
| EBITDA | $125.8M | $125.8M | $113.1M | $123.6M | $194.7M |
| EPS | 4.97 | 4.97 | 3.49 | 4.55 | 9.05 |
| Gross Margin | 22.8% | 22.8% | 23.5% | 24.8% | 32.8% |
| Operating Margin | 6.0% | 6.0% | 7.0% | 8.5% | 16.8% |
| Net Margin | 6.0% | 6.0% | 4.2% | 5.6% | 11.8% |
| Balance Sheet | |||||
| Debt/Equity | 0.07 | 0.07 | 0.08 | 0.08 | 0.08 |
| Current Ratio | 2.83 | 2.83 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $42.8M | $42.8M | $48.3M | $28.3M | $41.4M |
| Returns | |||||
| ROE | 8.1% | 8.1% | 6.0% | 8.2% | 16.7% |
| Valuation | |||||
| P/E | 11.27 | 11.27 | 2220.34 | 1340.66 | 1162.43 |
| EV/EBITDA | 459.97 | 459.97 | 765.31 | 551.40 | 608.66 |
| P/B | 84.72 | 84.72 | 134.10 | 109.48 | 193.53 |
| Growth & Yield | |||||
| Revenue Growth | 1.1% | 1.1% | 0.5% | 6.1% | — |
| EPS Growth | 42.4% | 42.4% | -23.3% | -49.7% | — |
| Dividend Yield | 4.0% | 4.0% | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
3Y implied EPS CAGR
352.4%
EPS terminal req.
$460.08
Spread vs growth
-310.0%
5Y implied EPS CAGR
157.0%
EPS terminal req.
$556.70
Spread vs growth
-114.5%
10Y implied EPS CAGR
68.1%
EPS terminal req.
$896.57
Spread vs growth
-25.7%
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-17.1%
Start / end P/E
1855.3x → 1028.4x
EPS bridge
3.49 → 4.97
Residual
-18.9%
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.